ヒト生殖技術の市場：タイプ、用途、エンドユーザー別-2025-2030年の世界予測

ヒト生殖技術市場は、2023年に298億4,000万米ドルと評価され、2024年には318億2,000万米ドルに達すると予測され、CAGR 6.66％で成長し、2030年には468億9,000万米ドルに達すると予測されています。

ヒト生殖技術は、医学的・科学的介入によるヒトの生殖補助を目的とした多様な治療と技術の集合です。この範囲には、体外受精（IVF）、人工授精、排卵誘発剤、代理出産、新たなゲノム技術などが含まれます。これらの技術の必要性は、主に出産の遅れ、ライフスタイル要因、特定の病状による不妊症の有病率の増加によってもたらされています。用途別では、不妊治療クリニック、病院、ヘルスケア研究機関で広く利用されています。最終用途は、子供を望む個人カップル、同性カップル、生殖補助を求める片親など多岐にわたる。

同市場は、生殖医療技術に対する認識と受容の高まり、医療科学の進歩、不妊治療ツーリズムに対する政府の支持的な規制によって大きな影響を受けています。さらに、新興国における可処分所得の上昇と医療インフラの充実が需要を牽引しています。しかし、治療費の高騰、倫理的・法的問題、患者の心理的ストレスの可能性などの制約があります。課題としては、社会的な偏見や、技術導入に影響を与える地域によって異なる法的枠組みなどが挙げられます。

潜在的な成長機会は、手頃な価格で利用しやすい治療法の開発、生殖技術を個人の遺伝子プロファイルに適合させる個別化医療、治療結果を効果的に予測する人工知能などの技術の進歩にあります。こうした機会を活用しようとする企業にとっては、革新的な不妊治療ソリューションを生み出すための研究開発への投資、より幅広いサービス提供のためのヘルスケアプロバイダーとのパートナーシップの形成、アクセシビリティと保険適用を支援する政策の提唱などが戦略的な一歩となりうる。イノベーションのホットスポットには、非侵襲的不妊診断、胚・配偶子凍結保存、患者参加・教育用モバイルヘルスアプリケーションなどがあります。この市場の特徴は、急速な技術進歩、競合の増加、倫理的・規制的状況を乗り越えながらアンメットニーズに効果的に対処するためのバイオテクノロジー企業、製薬企業、ヘルスケアセクター間の潜在的な協力関係です。

市場力学：急速に進化するヒト生殖技術市場の主要市場インサイトを公開

ヒト生殖技術市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • ライフスタイルの変化と不妊症および不妊関連疾患の有病率の上昇
  • 不妊治療を目的とした医療ツーリズムの増加
  • 不妊治療に対する認識と受容の高まり
• 市場抑制要因
  • 不妊治療に対する高額な費用と保険適用の制限
• 市場機会
  • より効果的な治療のためのヒト生殖技術の進歩と革新
  • 生殖技術の革新に対する特許と著作権
• 市場の課題
  • 限られた成功率とそれに伴う健康リスク

ポーターの5つの力：ヒト生殖技術市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ヒト生殖技術市場における外部からの影響の把握

外部マクロ環境要因は、ヒト生殖技術市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ヒト生殖技術市場における競合情勢の把握

ヒト生殖技術市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスヒト生殖技術市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ヒト生殖技術市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ヒト生殖技術市場における成功への道筋を描く

ヒト生殖技術市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ライフスタイルの変化と不妊症および不妊関連疾患の増加
    • 不妊治療に特化した医療ツーリズムの増加
    • 不妊治療に対する認識と受容の向上
  • 抑制要因
    • 不妊治療の高額な費用と保険適用範囲の制限
  • 機会
    • より効果的な治療のための人間の生殖技術の進歩と革新
    • 生殖技術の革新に関する特許と著作権
  • 課題
    • 成功率が限られており、それに伴う健康リスクがある
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ヒト生殖技術の市場：タイプ別

• 生殖補助医療
• 体外受精
• 子宮内人工授精
• 着床前遺伝子検査
• 代理出産

第7章 ヒト生殖技術の市場：用途別

• 生殖能力の保存
• 遺伝子検査
• 不妊治療

第8章 ヒト生殖技術の市場：エンドユーザー別

• 不妊治療クリニック
• 病院
• 調査・学術機関

第9章 南北アメリカのヒト生殖技術の市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のヒト生殖技術の市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのヒト生殖技術の市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• Aurobindo Pharma
• Bayer AG
• CooperSurgical Fertility Solutions
• Eli Lilly and Company
• European Sperm Bank
• Evofem Biosciences, Inc.
• Ferring B.V.
• GSK PLC
• InSEM Fertility Solutions
• INVO Bioscience
• KG Medical Industries
• Mankind Pharma
• Merck KGaA
• Microm UK Ltd.
• Monash IVF Group
• Pfizer Inc.
• Pride Angel
• Sandoz International GmbH
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• V Conceive
• Vitrolab AB
• Voxtur Bio Ltd.

LIST OF FIGURES

• FIGURE 1. HUMAN REPRODUCTIVE TECHNOLOGIES MARKET RESEARCH PROCESS
• FIGURE 2. HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. HUMAN REPRODUCTIVE TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HUMAN REPRODUCTIVE TECHNOLOGIES MARKET DYNAMICS
• TABLE 7. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY IN VITRO FERTILIZARTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY SURROGACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY FERTILITY PRESERVATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY GENETIC SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY INFERTILITY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. CANADA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. CANADA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. CHINA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. CHINA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. INDIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. INDIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. ITALY HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. ITALY HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. POLAND HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. POLAND HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. QATAR HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. QATAR HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. HUMAN REPRODUCTIVE TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. HUMAN REPRODUCTIVE TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2023

The Human Reproductive Technologies Market was valued at USD 29.84 billion in 2023, expected to reach USD 31.82 billion in 2024, and is projected to grow at a CAGR of 6.66%, to USD 46.89 billion by 2030.

Human Reproductive Technologies are a diverse set of treatments and technologies aimed at assisting human reproduction through medical and scientific interventions. This scope includes in vitro fertilization (IVF), artificial insemination, fertility drugs, surrogacy, and emerging genomics technologies. The necessity for these technologies is primarily driven by the increasing prevalence of infertility due to delayed childbearing, lifestyle factors, and certain medical conditions. Application-wise, they are extensively utilized in fertility clinics, hospitals, and healthcare research institutions. End-use spans across individual couples desiring children, same-sex couples, and single parents seeking reproductive assistance.

The market is significantly influenced by the growing awareness and acceptance of reproductive health technologies, advancements in medical sciences, and supportive government regulations for fertility tourism. Moreover, rising disposable income and better healthcare infrastructure in emerging economies drive demand. However, the market faces limitations such as high costs of treatment, ethical and legal concerns, and the potential for psychological stress among patients. Challenges include societal stigmas and varied legal frameworks across different regions impacting technology adoption.

Potential growth opportunities lie in developing affordable and accessible treatment options, personalized medicine adapting reproductive technologies to individual genetic profiles, and advancing technologies such as artificial intelligence to predict treatment outcomes effectively. For businesses looking to capitalize on these opportunities, investment in research and development to create innovative fertility solutions, forming partnerships with healthcare providers for wider service distribution, and advocating for policies that support accessibility and insurance coverage can be strategic steps. Innovation hotspots include non-invasive fertility diagnostics, embryo and gamete cryopreservation, and mobile health applications for patient engagement and education. The market is characterized by rapid technological advancements, increasing competition, and potential collaboration between biotechnology firms, pharmaceuticals, and healthcare sectors to address unmet needs effectively while navigating ethical and regulatory landscapes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Reproductive Technologies Market

The Human Reproductive Technologies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Changing lifestyles and rising prevalence of infertility and fertility-related disorders
  • Growing medical tourism for specialized fertility treatments
  • Increasing awareness and acceptance of fertility treatments
• Market Restraints
  • High cost and limited insurance coverage for fertility treatments
• Market Opportunities
  • Advancements and innovations in human reproductive technology for more effective treatment
  • Patents and copyrights for innovations in the reproductive technologies
• Market Challenges
  • Limited success rates and associated health risks

Porter's Five Forces: A Strategic Tool for Navigating the Human Reproductive Technologies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Reproductive Technologies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Reproductive Technologies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Reproductive Technologies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Reproductive Technologies Market

A detailed market share analysis in the Human Reproductive Technologies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Reproductive Technologies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Reproductive Technologies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Human Reproductive Technologies Market

A strategic analysis of the Human Reproductive Technologies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Reproductive Technologies Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Aurobindo Pharma, Bayer AG, CooperSurgical Fertility Solutions, Eli Lilly and Company, European Sperm Bank, Evofem Biosciences, Inc., Ferring B.V., GSK PLC, InSEM Fertility Solutions, INVO Bioscience, KG Medical Industries, Mankind Pharma, Merck KGaA, Microm UK Ltd., Monash IVF Group, Pfizer Inc., Pride Angel, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., V Conceive, Vitrolab AB, and Voxtur Bio Ltd..

Market Segmentation & Coverage

This research report categorizes the Human Reproductive Technologies Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Assisted Reproductive Technology, In Vitro Fertilizartion, Intrauterine Insemination, Preimplantation Genetic Testing, and Surrogacy.
• Based on Application, market is studied across Fertility Preservation, Genetic Screening, and Infertility Treatment.
• Based on End-User, market is studied across Fertility Clinics, Hospitals, and Research & Academic Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Changing lifestyles and rising prevalence of infertility and fertility-related disorders
    • 5.1.1.2. Growing medical tourism for specialized fertility treatments
    • 5.1.1.3. Increasing awareness and acceptance of fertility treatments
  • 5.1.2. Restraints
    • 5.1.2.1. High cost and limited insurance coverage for fertility treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements and innovations in human reproductive technology for more effective treatment
    • 5.1.3.2. Patents and copyrights for innovations in the reproductive technologies
  • 5.1.4. Challenges
    • 5.1.4.1. Limited success rates and associated health risks
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Human Reproductive Technologies Market, by Type

• 6.1. Introduction
• 6.2. Assisted Reproductive Technology
• 6.3. In Vitro Fertilizartion
• 6.4. Intrauterine Insemination
• 6.5. Preimplantation Genetic Testing
• 6.6. Surrogacy

7. Human Reproductive Technologies Market, by Application

• 7.1. Introduction
• 7.2. Fertility Preservation
• 7.3. Genetic Screening
• 7.4. Infertility Treatment

8. Human Reproductive Technologies Market, by End-User

• 8.1. Introduction
• 8.2. Fertility Clinics
• 8.3. Hospitals
• 8.4. Research & Academic Institutes

9. Americas Human Reproductive Technologies Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Human Reproductive Technologies Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Human Reproductive Technologies Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Aurobindo Pharma
• 4. Bayer AG
• 5. CooperSurgical Fertility Solutions
• 6. Eli Lilly and Company
• 7. European Sperm Bank
• 8. Evofem Biosciences, Inc.
• 9. Ferring B.V.
• 10. GSK PLC
• 11. InSEM Fertility Solutions
• 12. INVO Bioscience
• 13. KG Medical Industries
• 14. Mankind Pharma
• 15. Merck KGaA
• 16. Microm UK Ltd.
• 17. Monash IVF Group
• 18. Pfizer Inc.
• 19. Pride Angel
• 20. Sandoz International GmbH
• 21. Sun Pharmaceutical Industries Ltd.
• 22. Teva Pharmaceutical Industries Ltd.
• 23. V Conceive
• 24. Vitrolab AB
• 25. Voxtur Bio Ltd.